Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α

已完结 10 由大欣发布于 2025/3/26 9:56:02

DOI:10.1021/acs.oprd.4c00497
作者：Clayton Hardman, Artur K. Mailyan, Guillaume Mata, Joel W. Beatty, Samuel L. Drew, Jeremy Fournier, Jaroslaw Kalisiak, Brandon R. Rosen, Matthew Epplin, Balint Gal, Kai Yu, Zhang Wang, Karl Haelsig, A
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Casdatifan (AB521) is a potent and selective inhibitor of HIF-2α, currently under clinical evaluation for the treatment of clear cell renal cell carcinoma (ccRCC). Here, we report the develo

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Physical Society (APS)Strain tunability of magnetocrystalline anisotropy in Fe3GeTe2 thin films